Abstract
Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the westernized world and now represents a worldwide public health problem. NAFLD encompasses a broad spectrum of conditions, ranging from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH). The latter is recognized as a potentially progressive disease that could lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent rise in obesity likely explains the NAFLD epidemic worldwide. Recognition of the importance of NAFLD and its strong association with metabolic syndrome has stimulated interest in its putative role in the development of cardiovascular disease (CVD). Recently, accumulating evidence suggests that NAFLD is associated with a significant greater overall mortality, as well as with increased prevalence of CVD, both of which are independent of classical atherosclerotic risk factors. Furthermore, observation studies of natural history of NAFLD have shown that increased age-related mortality of NAFLD patients is attributable to CVD and liver-related diseases such as liver failure and hepatocellular carcinoma. In this paper, we review clinical data to support a strong association between NAFLD and CVD, and discuss possible underlying mechanisms for accelerated atherosclerosis in NAFLD.
Keywords: Nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis.
Current Pharmaceutical Design
Title:Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Volume: 20 Issue: 14
Author(s): Hideyuki Hyogo, Kazuaki Chayama and Sho-ichi Yamagishi
Affiliation:
Keywords: Nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis.
Abstract: Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the westernized world and now represents a worldwide public health problem. NAFLD encompasses a broad spectrum of conditions, ranging from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH). The latter is recognized as a potentially progressive disease that could lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent rise in obesity likely explains the NAFLD epidemic worldwide. Recognition of the importance of NAFLD and its strong association with metabolic syndrome has stimulated interest in its putative role in the development of cardiovascular disease (CVD). Recently, accumulating evidence suggests that NAFLD is associated with a significant greater overall mortality, as well as with increased prevalence of CVD, both of which are independent of classical atherosclerotic risk factors. Furthermore, observation studies of natural history of NAFLD have shown that increased age-related mortality of NAFLD patients is attributable to CVD and liver-related diseases such as liver failure and hepatocellular carcinoma. In this paper, we review clinical data to support a strong association between NAFLD and CVD, and discuss possible underlying mechanisms for accelerated atherosclerosis in NAFLD.
Export Options
About this article
Cite this article as:
Hyogo Hideyuki, Chayama Kazuaki and Yamagishi Sho-ichi, Nonalcoholic Fatty Liver Disease and Cardiovascular Disease, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990476
| DOI https://dx.doi.org/10.2174/13816128113199990476 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods
Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention
Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and ...read more
Management Of Primary And Metastatic Hepatic And Biliary Cancer
Cancer of the liver (primary and metastatic) and of the biliary tract is common wordwide. The pathophysiology is diverse. The therapeutic measures for the cancer of the liver and biliary tract include chemotherapy, surgery, transplantation, radiotherapy, immunotherapy and others. The aim of this thematic issue is to summarize the state-of-the-art ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Editorial (A Significant Step Towards New Altitude)
Current Molecular Medicine Modulation of Matrix Metalloproteinase Activity by Tobacco Cigarette Smoke
Current Chemical Biology Experimental and Comparison Based Study on Diabetes Prediction Using Artificial Neural Network
Recent Advances in Computer Science and Communications Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Dyslipidemia as a Risk Factor for Ischemic Stroke
Current Topics in Medicinal Chemistry Prion Protein Functions and Dysfunction in Prion Diseases
Current Medicinal Chemistry Preliminary Structural Studies of the Hydrophobic Ribosomal P0 Protein from Trypanosoma cruzi, A Part of the P0/P1/P2 Complex
Protein & Peptide Letters Editorial: The Need of Time: Development of New Antimicrobials
Current Topics in Medicinal Chemistry Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Use of Chou’s 5-steps Rule to Study the Effect of Cereal Dietary Protein on Liver and Coronary Heart Disease Prevention
Current Nutrition & Food Science Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Energy Metabolism in the Normal and in the Diabetic Heart
Current Pharmaceutical Design Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis
Current Cardiology Reviews Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Heart Rate Variability Analysis at Coronary Artery Disease and Angina Pectoris
Recent Patents on Cardiovascular Drug Discovery Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology





